Insmed Incorporated (INSM)
NASDAQ: INSM · Real-Time Price · USD
68.96
-1.84 (-2.60%)
Apr 24, 2025, 4:00 PM EDT - Market closed
Insmed Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Insmed stock have an average target of 95.36, with a low estimate of 63 and a high estimate of 110. The average target predicts an increase of 38.28% from the current stock price of 68.96.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Insmed stock from 16 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 9 | 9 | 9 | 9 | 9 | 9 |
| Buy | 7 | 7 | 7 | 7 | 7 | 7 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 16 | 16 | 16 | 16 | 16 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $90 | Strong Buy | Reiterates | $90 | +30.51% | Apr 22, 2025 |
| B of A Securities | B of A Securities | Strong Buy Maintains $92 → $96 | Strong Buy | Maintains | $92 → $96 | +39.21% | Mar 20, 2025 |
| RBC Capital | RBC Capital | Buy Reiterates $100 | Buy | Reiterates | $100 | +45.01% | Mar 19, 2025 |
| UBS | UBS | Strong Buy Maintains $105 → $110 | Strong Buy | Maintains | $105 → $110 | +59.51% | Mar 6, 2025 |
| RBC Capital | RBC Capital | Buy Initiates $100 | Buy | Initiates | $100 | +45.01% | Feb 25, 2025 |
Financial Forecast
Revenue This Year
473.41M
from 363.71M
Increased by 30.16%
Revenue Next Year
1.02B
from 473.41M
Increased by 115.67%
EPS This Year
-5.45
from -5.57
EPS Next Year
-3.81
from -5.45
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 510.4M | 1.5B | 2.4B | ||
| Avg | 473.4M | 1.0B | 1.9B | ||
| Low | 432.6M | 790.1M | 1.4B |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 40.3% | 213.0% | 139.7% | ||
| Avg | 30.2% | 115.7% | 83.5% | ||
| Low | 18.9% | 66.9% | 40.4% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -4.86 | -1.64 | 2.91 | ||
| Avg | -5.45 | -3.81 | -0.82 | ||
| Low | -5.90 | -6.18 | -2.68 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.